ヴトリシランの世界市場レポート 2025年

ヴトリシラン市場規模は、今後数年で急成長が見込まれます。2029年には12.4%のCAGRで10億8,000万米ドルに成長します。予測期間における成長の原動力は、ヘルスケアの利用可能性の拡大、慢性疾患の有病率の上昇、研究開発投資の増加、個別化医療の重視の高まり、疾患に対する意識の高まりです。主な動向としては、併用療法の進展、標的療法の採用、個別化医療の進展、デジタルヘルス技術の開発、バイオテクノロジーの革新などが挙げられます。

研究開発への投資の増加は、今後数年間のヴトリシラン市場の成長を促進すると予想されます。研究開発には、体系的な調査や実験を通じて、製品やサービス、プロセスを革新・強化することが含まれます。研究開発投資の増加は、政府のイニシアチブと資金提供、ヘルスケアと医薬品需要の増加、持続可能性への取り組み、環境への懸念に起因しています。研究開発への資金提供により、製薬企業は臨床試験を実施し、医薬品の長期的な有効性と安全性を実証し、より幅広い規制当局の承認につなげることができます。さらに、RNA干渉（RNAi）技術の進歩により、薬剤の精度が向上し、副作用が最小限に抑えられ、患者への普及が進みます。例えば、2023年12月、ルクセンブルクを拠点とする欧州連合（EU）の統計局であるユーロスタットは、EUの研究開発費が2022年に3,520億ユーロ（3,844億2,000万米ドル）に達し、前年の3,310億ユーロ（3,614億8,000万米ドル）から6.34％増加したと報告しました。その結果、研究開発投資の増加がヴトリシラン市場の拡大に拍車をかけています。

ヴトリシラン市場で事業を展開する企業は、遺伝性トランスサイレチン介在性（hATTR）アミロイドーシスを管理するために、より便利で投与頻度の少ない選択肢を提供する皮下RNAi治療薬などの革新的な治療法の開発に注力しています。これらの治療薬はRNA干渉技術を利用し、皮下注射によって投与され、持続的な薬物放出を保証します。このアプローチにより、長期にわたって薬物濃度が一定に保たれるため、遺伝性トランスサイレチン介在性（hATTR）アミロイドーシスに伴う多発性神経障害の治療において、患者の利便性とアドヒアランスが向上します。例えば、2022年6月、米国のバイオ医薬品会社であるアルナイラム・ファーマシューティカルズ社は、ヴトリシラン（AMVUTTRA）が遺伝性トランスサイレチンを介する（hATTR）アミロイドーシスの成人における多発性神経障害の治療薬として食品医薬品局（FDA）から承認を取得したと発表しました。本剤は神経障害の症状を大幅に緩和し、疾患の進行を遅らせる。HELIOS-A第3相試験では、50％以上の患者で病状の逆転または停止が認められました。AMVUTTRAは良好な安全性プロファイルを示し、薬剤に関連した投与中止や死亡例はなく、患者のコンプライアンスを高める投与法を特徴としています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ヴトリシランPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のヴトリシラン市場：成長率分析
• 世界のヴトリシラン市場の実績：規模と成長, 2019-2024
• 世界のヴトリシラン市場の予測：規模と成長, 2024-2029, 2034F
• 世界ヴトリシラン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のヴトリシラン市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アンチセンスオリゴヌクレオチド
• 核酸
• ヌクレオチド
• ヌクレオシド
• その他の薬物クラス
• 世界のヴトリシラン市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• 皮下
• 世界のヴトリシラン市場患者の人口統計別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小児科
• 成人用
• 高齢者
• 世界のヴトリシラン市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• その他の流通チャネル
• 世界のヴトリシラン市場アンチセンスオリゴヌクレオチドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 一本鎖アンチセンスオリゴヌクレオチド
• 二本鎖アンチセンスオリゴヌクレオチド
• 世界のヴトリシラン市場核酸の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• DNAベースの核酸
• RNAベースの核酸
• 世界のヴトリシラン市場ヌクレオチドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プリンヌクレオチド
• ピリミジンヌクレオチド
• 世界のヴトリシラン市場ヌクレオシドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プリンヌクレオシド
• ピリミジンヌクレオシド
• 世界のヴトリシラン市場、その他の薬物クラスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ペプチドベースの医薬品
• プロテインセラピューティクス

第7章 地域別・国別分析

• 世界のヴトリシラン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のヴトリシラン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ヴトリシラン市場：競合情勢
• ヴトリシラン市場：企業プロファイル
  • Alnylam Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 世界の市場競合ベンチマーキングとダッシュボード

第32章 主要な合併と買収

第33章 最近の市場動向

第34章 市場の潜在力が高い国、セグメント、戦略

• ヴトリシラン市場2029：新たな機会を提供する国
• ヴトリシラン市場2029：新たな機会を提供するセグメント
• ヴトリシラン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第35章 付録

Vutrisiran is a small interfering RNA (siRNA) therapy used to treat hereditary transthyretin-mediated (hATTR) amyloidosis. It works by silencing the transthyretin (TTR) gene, reducing abnormal TTR protein deposits responsible for polyneuropathy and organ damage. Vutrisiran helps slow disease progression while improving neurological function, mobility, and overall quality of life, offering the benefit of a longer dosing interval.

The primary drug classes for vutrisiran include antisense oligonucleotides, nucleic acids, nucleotides, nucleosides, and others. Antisense oligonucleotides (ASOs) are synthetic short DNA or RNA molecules designed to target specific mRNA sequences and regulate gene expression. Vutrisiran is administered through various routes, including oral, injectable, and subcutaneous, and is suitable for different patient demographics, including pediatric, adult, and geriatric populations. It is distributed through multiple channels, such as hospital pharmacies, retail pharmacies, online pharmacies, and others.

The vutrisiran market research report is one of a series of new reports from The Business Research Company that provides vutrisiran market statistics, including the vutrisiran industry global market size, regional shares, competitors with the vutrisiran market share, detailed vutrisiran market segments, market trends, and opportunities, and any further data you may need to thrive in the vutrisiran industry. This vutrisiran market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The vutrisiran market size has grown rapidly in recent years. It will grow from $0.60 billion in 2024 to $0.68 billion in 2025 at a compound annual growth rate (CAGR) of 12.8%. The growth during the historic period can be attributed to increasing awareness of hereditary transthyretin amyloidosis, a rise in clinical trials, growing healthcare spending, a higher patient preference for non-invasive administration methods, and an increasing prevalence of genetic disorders.

The vutrisiran market size is expected to see rapid growth in the next few years. It will grow to $1.08 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The projected growth in the forecast period is driven by expanding healthcare availability, a rising prevalence of chronic diseases, increased investment in research and development, a growing emphasis on personalized medicine, and greater awareness of the disease. Key trends include advancements in combination therapy, the adoption of targeted therapy, progress in personalized medicine, the development of digital health technologies, and innovations in biotechnology.

The increasing investment in research and development is expected to drive the growth of the vutrisiran market in the coming years. Research and development involve innovating and enhancing products, services, or processes through systematic investigation and experimentation. The rise in R&D investment is attributed to government initiatives and funding, increasing healthcare and pharmaceutical demands, sustainability efforts, and environmental concerns. Funding for research and development enables pharmaceutical companies to conduct clinical trials, demonstrating the drug's long-term efficacy and safety, leading to wider regulatory approvals. Additionally, advancements in RNA interference (RNAi) technology enhance the drug's precision, minimizing side effects and increasing patient adoption. For example, in December 2023, Eurostat, a Luxembourg-based statistical office of the European Union, reported that the European Union's research and development expenditure reached €352 billion ($384.42 billion) in 2022, reflecting a 6.34% increase from €331 billion ($361.48 billion) in the previous year. As a result, rising investments in research and development are fueling the expansion of the vutrisiran market.

Companies operating in the vutrisiran market are focusing on developing innovative treatments, such as subcutaneous RNAi therapeutics, to offer more convenient and less frequent dosing options for managing hereditary transthyretin-mediated (hATTR) amyloidosis. These therapeutics utilize RNA interference technology and are administered through injections under the skin, ensuring sustained drug release. This approach maintains consistent drug levels over time, enhancing patient convenience and adherence in treating polyneuropathy associated with hereditary transthyretin-mediated (hATTR) amyloidosis. For example, in June 2022, Alnylam Pharmaceuticals, a US-based biopharmaceutical company, announced that vutrisiran (AMVUTTRA) received approval from the Food and Drug Administration (FDA) for the treatment of polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis. The drug significantly alleviates neuropathy symptoms and slows disease progression. In the HELIOS-A Phase 3 study, more than 50% of patients showed a reversal or halt in disease manifestations. AMVUTTRA has demonstrated a favorable safety profile, with no drug-related discontinuations or fatalities, and features a dosing regimen that may enhance patient compliance.

In April 2024, Medison Pharma, an Israel-based pharmaceutical company, collaborated with Alnylam Pharmaceuticals Inc. to extend the commercialization of RNAi therapeutics. This partnership seeks to increase global availability of Alnylam's innovative RNAi treatments, particularly for patients with rare diseases, by leveraging Medison's integrated commercialization platform across multiple regions, including LATAM, APAC, and other international markets. Alnylam Pharmaceuticals, Inc. is a US-based pharmaceutical company that manufactures vutrisiran.

The key player in the vutrisiran market is Alnylam Pharmaceuticals Inc.

North America was the largest region in the vutrisiran market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in vutrisiran report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vutrisiran market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vutrisiran market consists of sales of pre-filled syringes and vials for subcutaneous injection. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vutrisiran Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vutrisiran market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vutrisiran ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vutrisiran market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Antisense Oligonucleotide; Nucleic Acids; Nucleotide; Nucleoside; Other Drug Classes
• 2) By Route Of Administration: Oral; Injectable; Subcutaneous
• 3) By Patient Demographics: Pediatric; Adult; Geriatric
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Antisense Oligonucleotide: Single-Stranded Antisense Oligonucleotides; Double-Stranded Antisense Oligonucleotides
• 2) By Nucleic Acids: DNA-based Nucleic Acids; RNA-based Nucleic Acids
• 3) By Nucleotide: Purine Nucleotides; Pyrimidine Nucleotides
• 4) By Nucleoside: Purine Nucleosides; Pyrimidine Nucleosides
• 5) By Other Drug Classes: Peptide-Based Drugs; Protein Therapeutics
• Companies Mentioned: Alnylam Pharmaceuticals Inc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Vutrisiran Market Characteristics

3. Vutrisiran Market Trends And Strategies

4. Vutrisiran Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Vutrisiran Growth Analysis And Strategic Analysis Framework

• 5.1. Global Vutrisiran PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Vutrisiran Market Growth Rate Analysis
• 5.4. Global Vutrisiran Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Vutrisiran Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Vutrisiran Total Addressable Market (TAM)

6. Vutrisiran Market Segmentation

• 6.1. Global Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antisense Oligonucleotide
• Nucleic Acids
• Nucleotide
• Nucleoside
• Other Drug Classes
• 6.2. Global Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Subcutaneous
• 6.3. Global Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric
• Adult
• Geriatric
• 6.4. Global Vutrisiran Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
• 6.5. Global Vutrisiran Market, Sub-Segmentation Of Antisense Oligonucleotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single-Stranded Antisense Oligonucleotides
• Double-Stranded Antisense Oligonucleotides
• 6.6. Global Vutrisiran Market, Sub-Segmentation Of Nucleic Acids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• DNA-based Nucleic Acids
• RNA-based Nucleic Acids
• 6.7. Global Vutrisiran Market, Sub-Segmentation Of Nucleotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Purine Nucleotides
• Pyrimidine Nucleotides
• 6.8. Global Vutrisiran Market, Sub-Segmentation Of Nucleoside, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Purine Nucleosides
• Pyrimidine Nucleosides
• 6.9. Global Vutrisiran Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Peptide-Based Drugs
• Protein Therapeutics

7. Vutrisiran Market Regional And Country Analysis

• 7.1. Global Vutrisiran Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Vutrisiran Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Vutrisiran Market

• 8.1. Asia-Pacific Vutrisiran Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Vutrisiran Market

• 9.1. China Vutrisiran Market Overview
• 9.2. China Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Vutrisiran Market

• 10.1. India Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Vutrisiran Market

• 11.1. Japan Vutrisiran Market Overview
• 11.2. Japan Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Vutrisiran Market

• 12.1. Australia Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Vutrisiran Market

• 13.1. Indonesia Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Vutrisiran Market

• 14.1. South Korea Vutrisiran Market Overview
• 14.2. South Korea Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Vutrisiran Market

• 15.1. Western Europe Vutrisiran Market Overview
• 15.2. Western Europe Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Vutrisiran Market

• 16.1. UK Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Vutrisiran Market

• 17.1. Germany Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Vutrisiran Market

• 18.1. France Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Vutrisiran Market

• 19.1. Italy Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Vutrisiran Market

• 20.1. Spain Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Vutrisiran Market

• 21.1. Eastern Europe Vutrisiran Market Overview
• 21.2. Eastern Europe Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Vutrisiran Market

• 22.1. Russia Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Vutrisiran Market

• 23.1. North America Vutrisiran Market Overview
• 23.2. North America Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Vutrisiran Market

• 24.1. USA Vutrisiran Market Overview
• 24.2. USA Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Vutrisiran Market

• 25.1. Canada Vutrisiran Market Overview
• 25.2. Canada Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Vutrisiran Market

• 26.1. South America Vutrisiran Market Overview
• 26.2. South America Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Vutrisiran Market

• 27.1. Brazil Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Vutrisiran Market

• 28.1. Middle East Vutrisiran Market Overview
• 28.2. Middle East Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Vutrisiran Market

• 29.1. Africa Vutrisiran Market Overview
• 29.2. Africa Vutrisiran Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Vutrisiran Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Vutrisiran Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Vutrisiran Market Competitive Landscape And Company Profiles

• 30.1. Vutrisiran Market Competitive Landscape
• 30.2. Vutrisiran Market Company Profiles
  • 30.2.1. Alnylam Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Global Vutrisiran Market Competitive Benchmarking And Dashboard

32. Key Mergers And Acquisitions In The Vutrisiran Market

33. Recent Developments In The Vutrisiran Market

34. Vutrisiran Market High Potential Countries, Segments and Strategies

• 34.1 Vutrisiran Market In 2029 - Countries Offering Most New Opportunities
• 34.2 Vutrisiran Market In 2029 - Segments Offering Most New Opportunities
• 34.3 Vutrisiran Market In 2029 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer